
Speciale Invest's Fund III closes at Rs 600 crore; eyes investing in 18-20 deeptech startups
The Chennai-based venture capital (VC) firm said it will back 18-20 early-stage deeptech startups in sectors such as artificial intelligence (AI) infrastructure, spacetech, climatetech, quantum systems, advanced manufacturing, and dual-use defence. The initial ticket sizes will range from Rs 7 to Rs 10 crore, with the flexibility to go higher in some cases.
Vishesh Rajaram, managing director at Speciale, said the interest of institutional investors, family offices, and HNIs in the deeptech sector has grown significantly. 'Over 50% of Fund III capital is from repeat Limited Partners (LPs), and we also have new institutions and corporate VCs,' he told ET. Speciale said conviction in India's deeptech opportunity has strengthened. The firm will continue to invest in 'zero to one' startups at the pre-seed level. So far, the VC firm has bet on startups such as Agnikul Cosmos, GalaxEye, ePlane Company, Ultraviolette, CynLr, and QNu Labs. It has also made nine mergers and acquisitions (M&A) exits.'A large learning from our Fund I and II has been that this is the best time to build sovereign-edge technologies in the country and begin serving global needs,' said Speciale's Rajaram. He added that India's geopolitical position also calls for reducing dependence on certain foreign technologies. Out of the Rs 600 crore fund, Rs 300 crore will be reserved for follow-up investments.
Speciale is not the only fund to focus on IP and advanced manufacturing. Last week, Accel announced a significant shift in its theses, eyeing IP-driven startups in sectors like aerospace, electric vehicle (EV) components, and medical devices. The firm, in January, announced an early-stage fund of $650 million, specifically for startups in India and Southeast Asia. In its Fund III, Speciale intends to increase the average ownership in startups. 'In Fund I, we owned about 5% of each company; in Fund II, around 10%; now, with Fund III, we'll target about 15%. The round sizes and company stages stay the same, but we aim for more ownership and a larger follow-on capital reserve of about 50%,' Rajaram said, who earlier was a principal at Ventureast, a $100 million early and growth stage fund.Venture capitalists noted that with startups thinking global first and looking at selling in global markets from day one, the existing timelines may come down by a year. Despite the growing trend, Rajaram reiterated that deeptech will need a long gestation period, and for a 'good exit, one that can return the fund, it will typically take 6-10 years.' Elevate your knowledge and leadership skills at a cost cheaper than your daily tea. As 50% US tariff looms, 6 key steps that can safeguard Indian economy
As big fat Indian wedding slims to budget, Manyavar loses lustre
Why are mid-cap stocks fizzling out? It's not just about Trump tariffs.
The airport lounge war has begun — and DreamFolks is losing
Stock Radar: UNO Minda eyeing fresh 52-week high in next few weeks; check target and stop loss for long positions
Buy, Sell or Hold: Antique recommends buy on Siemens; Avendus upgrades SBI to Buy post June quarter results
Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 25%
Weekly Top Picks: These stocks scored 10 on 10 on Stock Reports Plus

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Economic Times
12 minutes ago
- Economic Times
Intas Pharma completes acquisition of UDENYCA biosimilar for $558 million
Synopsis Intas Pharma finalized its acquisition of UDENYCA, a biosimilar to Neulasta, from Coherus Life Sciences for $558 million in December 2024. This acquisition strengthens Intas's position as a global leader in pegfilgrastim. Accord BioPharma, Intas's U.S. specialty business, will continue commercializing UDENYCA to reduce infection risk in cancer patients undergoing myelosuppressive chemotherapy. Agencies Intas Pharma has completed the acquisition of UDENYCA for $558 million, the company said in a release. UDENYCA is a biosimilar to Neulasta or Pegfilgrastim. It is used to treat side effects of radiation therapy in cancer patients such as recurrent infections. Intas acquired the biosimilar drug from California-based Coherus Life Sciences in December 2024.'This acquisition cements our position as a global leader in pegfilgrastim and allows us to further expand our specialty division across key international markets,' said Binesh Chudgar, Intas Pharma's chairman and managing Pharmaceuticals in collaboration with its global subsidiaries operating under the Accord brand, have acquired UDENYCA. With the acquisition, Accord BioPharma, the U.S. specialty business of Intas, continues the commercialization of UDENYCA to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia, the company's release stated.'The completion of the UDENYCA acquisition marks a pivotal moment for Accord BioPharma, as it not only strengthens our market presence but broadens our capabilities as we endeavour to innovate and expand in the biosimilar space,' said Chrys Kokino, President, USA, Accord BioPharma.


Economic Times
14 minutes ago
- Economic Times
Nykaa shares rally 5% as brokerages turn more bullish post Q1 results. Should you buy, sell or hold?
Nykaa shares rose 5.4% to Rs 215.95 after brokerages reaffirmed bullish views post-Q1 results. Net profit jumped 79% YoY to Rs 24 crore, revenue grew 23% to Rs 2,155 crore, and GMV climbed 26% to Rs 4,182 crore. Nuvama and JM Financial maintained Buy ratings, citing strong beauty growth, improving fashion performance, and margin expansion potential. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Q1 performance supports outlook Shares of FSN E-Commerce, which operates the Nykaa brand, climbed as much as 5.4% on Wednesday to Rs 215.95 on the BSE after brokerages reaffirmed bullish views and raised price targets following the company's first-quarter maintained its Buy rating on Nykaa with a target price of Rs 235, implying a 15% upside from the stock's last traded price. The brokerage said market share gains remain a strategic priority, with strong momentum in the Beauty & Personal Care segment and improving growth in expects around 20% GMV growth and margin expansion, supported by narrowing losses in the Fashion and eB2B businesses. However, Nuvama trimmed earnings estimates for FY26 and FY27 by 10% and 12%, respectively, due to higher tax assumptions. JM Financial reiterated its Buy call and raised its target price to Rs 260 from Rs 250, implying a potential upside of 27.5% from the last traded brokerage noted that Nykaa delivered robust growth despite a tepid demand environment, with the Beauty & Personal Care vertical posting 26% GMV growth and offline retail rising 33% Financial expects an accelerated improvement in consolidated EBITDA margins, driven by higher profitability in core beauty operations and declining losses in Fashion and reported a 79% year-on-year jump in consolidated net profit to Rs 24 crore for the quarter ended June 30, 2025, on a 23% increase in revenue from operations to Rs 2,155 grew 26% to Rs 4,182 crore, with the Beauty vertical contributing Rs 3,208 crore. EBITDA rose 46% from a year earlier, with margins expanding to 6.5% from 5.5%.The House of Nykaa Beauty business now accounts for 18% of the company's overall beauty GMV, said Falguni Nayar, founder and CEO of Nykaa.'Since our IPO, we have consistently delivered mid-20s growth at a consolidated level. Our cumulative customer base now stands at 45 million, reflecting the growing trust and adoption of our platform,' Nayar added.


Scroll.in
14 minutes ago
- Scroll.in
RPSC ASO application window closes today for 43 posts; here's how to register
The Rajasthan Public Service Commission (RPSC) will close the online application window for the recruitment of Assistant Statistical Officer (Eco. and Stat. Dept.) 2024 posts under Advt. No. 09/2024-25. Eligible candidates can apply for the posts on the official website or The recruitment drive aims to fill up a total of 43 ASO posts. Applicants can check the eligibility criteria, age limit, pay scale, and other details available in the notification below: Here's the official notification. Candidates have to pay a fee of Rs 750 for One Time Registration (OTR). More details in the notification. Steps to register for ASO posts 2024